Opko Expands Prostate Cancer Biomarker Licensing Deal as Part of Commercialization Plan

Mar 23, 2012

Premium

Opko Health said this week that it has expanded a licensing deal with Finnish biotech firm Artic Partners for prostate cancer protein biomarkers that it announced in January (PM 1/30/2012).

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

The Scan

This Week in PNAS

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.

Leaving It All Over Town

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.

Balance of Research and Privacy

A panel at the New York Times discusses anonymity and privacy of users of 23andMe's services when access to its database is offered for research.

What We'd Do With the Money

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.

Featured White Papers

Reverse Phase Protein Arrays for Cell Signaling: Using the InnoScan 710-IR scanner improves sensitivity and dynamic range.

Infrared detection decreases nitrocellulose autofluorescence and improves RPPA assays signal‐to‐noise ratio over visible wavelength detection

Mar

05

Featured Webinar

Integrating Metabolomic and Proteomic Profiles for 'Less Impersonal' Medicine

In this live webcast, Robert Gerszten of Massachusetts General Hospital will describe an ongoing project that is integrating metabolic and proteomic profiling to gain a better understanding of cardiometabolic disease.

Main menu